Nitrofurantoin‑Induced Pneumonitis in Patients with Prior Sulfonamide‑Induced Lung Injury

Risk Assessment

Patients who have previously experienced drug‑induced pneumonitis (e.g., from sulfonamides) have an underlying predisposition that increases the likelihood of developing pulmonary hypersensitivity reactions when exposed to other pneumotoxic antibiotics such as nitrofurantoin. 1

Clinicians should explicitly inform patients with a history of sulfonamide‑related pneumonitis that their risk of nitrofurantoin‑induced lung toxicity is elevated. 1
Prior to initiating nitrofurantoin, a baseline assessment of pulmonary status—including a review of current respiratory symptoms and, when chronic use is anticipated, a baseline chest radiograph—should be performed to identify any residual lung injury from the earlier sulfa reaction. 1

If nitrofurantoin therapy proceeds, patients must be instructed to promptly report new dyspnea, cough, chest pain, or fever, and a clinical review should be scheduled at approximately one week to surveil for acute hypersensitivity. (Monitoring recommendation derived from the cited guidance.) 1
At the first indication of pulmonary symptoms, nitrofurantoin should be stopped immediately, and a chest CT scan obtained to evaluate for ground‑glass opacities or infiltrates consistent with drug‑induced pneumonitis. 1

When nitrofurantoin is contraindicated due to pneumonitis risk, alternative agents without significant pneumotoxicity should be considered, such as:

Factors associated with unfavorable prognosis in nitrofurantoin‑related lung injury include:

Cancer chemotherapy agents, particularly bleomycin, are the most common cause of drug-induced pneumonitis, followed by drugs for autoimmune diseases (methotrexate), amiodarone, and antibiotics (nitrofurantoin) 2
Carmustine can cause delayed pulmonary fibrosis, sometimes occurring beyond 10 years after treatment completion 2
Docetaxel causes pneumonitis with a hypersensitivity pattern 3
EGFR inhibitors (erlotinib, gefitinib, afatinib, osimertinib) cause pneumonitis in 0.55-4.77% of patients, with higher rates in Japanese populations 4
ALK inhibitors (alectinib, brigatinib, ceritinib, crizotinib) cause pneumonitis in 1.14-6.25% of patients, again with higher rates in Japanese cohorts 4, 5
mTOR inhibitors (everolimus) cause organizing pneumonia pattern 3
PD-1 inhibitors (nivolumab, pembrolizumab) cause pneumonitis in 2.7% of patients on monotherapy and 6.6% on combination therapy 3
PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) cause pneumonitis in approximately 1.3% of patients 6
CTLA-4 inhibitors (ipilimumab) are associated with immune-related pneumonitis 5
Rituximab (CD20 antibody) caused pneumonitis in 121 reported cases, with 15% mortality and diffuse alveolar damage pattern 5
Amiodarone is a well-established cause, with pulmonary toxicity including pneumonitis, ARDS, and bronchiolitis obliterans organizing pneumonia 2
Nitrofurantoin is a common antibiotic culprit 2

Japanese populations demonstrate significantly higher pneumonitis rates with EGFR and ALK inhibitors (4.77% vs 0.55% for gefitinib; 6.25% vs 1.14% for ALK inhibitors in Japanese vs non-Japanese cohorts) 4, 5

Age ≥55 years, ECOG performance status 2-4, smoking history, pre-existing or concurrent interstitial lung disease, and comorbid pleural effusion are significant risk factors for developing drug-induced pneumonitis, particularly with crizotinib 5